AbbVie Inc. closed 15.13% below its 52-week high of $218.66, which the company reached on March 10th.

AbbVie is strutting into 2025 like it owns the lab, thanks to a performance cocktail of smart acquisitions, clinical wins, ...

Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics ...

AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...

AbbVie’s stock faced a chilly reception on May 6, plunging 4.55% and ending the day at $187.15. Despite strong fundamentals ...

After a two-year surge of 53%, the stock market has been taken for a wild ride in 2025, driven by uncertainties surrounding ...

Ironwood Pharmaceuticals, Inc.’s IRWD share price has surged by 5.57%, which has investors questioning if this is right time ...

AbbVie ( NYSE: ABBV) shares snapped seven straight sessions of gains, as the stock was down 0.9% at $193.40 on Thursday. The maker of Humira arthritis therapy added over 12% in the preceding seven ...

Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in ...

The Graham number is often used in isolation, but in fact it is only one part of a check list for choosing defensive stocks that he laid out in Chapter 14 of The Intelligent Investor. The analysis ...

Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 10 years ago, it would be worth $300.66 today based on a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.